Autoimmunity reviews最新文献

筛选
英文 中文
Soluble CD137 in health and disease: A systematic review and meta-analysis. 可溶性CD137在健康和疾病中的作用:一项系统综述和荟萃分析
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-14 DOI: 10.1016/j.autrev.2026.104233
Sixuan Liu, Yeny Acosta-Ampudia, Carolina Ramírez-Santana, Diana M Monsalve, William Harper, Nicolle Sweeny, Luke S Heuer, Weici Zhang, William M Ridgway, Manuel Rojas
{"title":"Soluble CD137 in health and disease: A systematic review and meta-analysis.","authors":"Sixuan Liu, Yeny Acosta-Ampudia, Carolina Ramírez-Santana, Diana M Monsalve, William Harper, Nicolle Sweeny, Luke S Heuer, Weici Zhang, William M Ridgway, Manuel Rojas","doi":"10.1016/j.autrev.2026.104233","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104233","url":null,"abstract":"<p><strong>Background: </strong>Soluble CD137 (sCD137), produced by regulatory T cells, plays a critical role in immune response regulation. Its measured presence in serum highlights sCD137 as a potential biomarker for diagnosis and treatment monitoring across several conditions, including autoimmunity, cancer, and infectious diseases. However, inconsistent findings across studies call for a systematic review to clarify its clinical value.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a comprehensive search across medical databases identified studies on sCD137 in healthy and diseased patients. Two researchers independently screened, extracted data, and assessed study quality. We conducted a random-effects meta-analysis to estimate the pooled standardized mean difference (SMD) between patient groups and healthy controls, as well as changes in sCD137 levels pre- and post-treatment. Meta-regression analysis was conducted to evaluate the effect of age, geographical location, study design, and measurement technique on sCD137 levels. 4372+.</p><p><strong>Results: </strong>A total of 47 articles and 4854 individuals, of which 480 provided pre- and post-treatment data, were included in the analysis. Diseased patients exhibited higher levels of sCD137 than healthy controls (SMD: 1.11, 95% CI, 0.76 to 1.46). More specifically, elevation in sCD137 was consistent in patients with infectious conditions (SMD: 1.78, 95% CI, 0.08 to 3.47), autoimmune diseases (SMD: 0.95, 95% CI, 0.25 to 1.65), and cancer (SMD: 0.79, 95% CI, 0.23 to 1.34). Pre- and post-treatment analysis demonstrated that therapy reduced the levels of sCD137 in autoimmunity (SMD: -0.73, 95% CI, -1.24 to -0.23), whereas cancer therapies had the opposite effect (SMD: 1.14, 95% CI, 0.60 to 1.67). Age, geographical location, epidemiological design, or sCD137 measurement technique did not influence pooled estimates.</p><p><strong>Conclusion: </strong>In this exploratory meta-analysis, circulating sCD137 levels were consistently higher in patients than in healthy controls and showed treatment-associated changes in both autoimmune and cancer settings. However, because sCD137 primarily reflects ongoing immunoregulatory activity, and because the underlying immune mechanisms differ substantially across and even within disease categories, its interpretation as a biomarker must remain strictly context-dependent.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104233"},"PeriodicalIF":9.8,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms bridging autoimmunity and autoinflammation in axial spondyloarthritis: current evidence and translational implications. 轴性脊柱炎中连接自身免疫和自身炎症的机制:目前的证据和翻译意义。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-13 DOI: 10.1016/j.autrev.2026.104249
Diana Maria Margareta Moldovan, Nuria Barbarroja, Ruxandra Elena Schiotis, Daniela Fodor, Eduardo Collantes-Estévez, Clementina López-Medina
{"title":"Mechanisms bridging autoimmunity and autoinflammation in axial spondyloarthritis: current evidence and translational implications.","authors":"Diana Maria Margareta Moldovan, Nuria Barbarroja, Ruxandra Elena Schiotis, Daniela Fodor, Eduardo Collantes-Estévez, Clementina López-Medina","doi":"10.1016/j.autrev.2026.104249","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104249","url":null,"abstract":"<p><p>Axial spondyloarthritis (axSpA) illustrates the limitations of classifying immune-mediated diseases as strictly autoimmune or autoinflammatory. Its strong association with HLA-B27 and epistatic interaction with endoplasmic reticulum aminopeptidase 1 (ERAP1) support a contribution from adaptive immunity through altered antigen processing and presentation. At the same time, axSpA lacks high-titre, disease-defining autoantibodies and preferentially affects mechanically loaded sites, including the entheses and sacroiliac joints. Mucosal barrier dysfunction, innate and stromal responses, and IL-17A production by several lymphocyte populations are also implicated. However, findings from blood, peripheral synovium, gut, ligament and non-inflamed enthesis cannot be assumed to represent the same axial lesion. This critical narrative review examines how adaptive, innate and stromal processes may interact in axSpA. \"Bridging mechanism\" is used as a working term for a directional and testable relationship across an adaptive-innate immunity or immune-stromal boundary, anchored to a defined phenotype, tissue and study system. It does not replace the established autoimmune-autoinflammatory continuum or MHC-I-opathy concepts. Evidence remains uneven. HLA-B27-related stress and receptor interactions, defined alarmin-stromal experiments and ligament-derived extracellular-vesicle transfer are evaluated within their specific experimental contexts, whereas anti-CD74 antibodies, circulating microRNAs, DN2 B-cell changes and the FOXO1-SIRT1 axis remain associative or exploratory. Inhibitors targeting TNF, IL-17A/IL-17F and Janus kinase pathways are clinically effective in defined axSpA populations, whereas IL-23-pathway inhibition has not demonstrated efficacy in established axial disease. Several explanations remain possible, but these trials do not identify a specific IL-23-independent cellular circuit. By considering supportive, conflicting and negative findings together, this review identifies the evidence still needed before candidate mechanisms or biomarkers can inform treatment decisions or help predict structural progression.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104249"},"PeriodicalIF":9.8,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A unifying perspective on EBV-triggered CNS autoimmune diseases: from permissive conditions to intrathecal B-cell activation. ebv引发的CNS自身免疫性疾病的统一观点:从允许条件到鞘内b细胞活化
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-12 DOI: 10.1016/j.autrev.2026.104237
Han Li, Sijia Hou, Wei Jiang
{"title":"A unifying perspective on EBV-triggered CNS autoimmune diseases: from permissive conditions to intrathecal B-cell activation.","authors":"Han Li, Sijia Hou, Wei Jiang","doi":"10.1016/j.autrev.2026.104237","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104237","url":null,"abstract":"<p><p>Epstein-Barr virus (EBV) is a major environmental risk factor for multiple sclerosis (MS) and has also been linked-though with limited evidence-to other central nervous system (CNS) autoimmune diseases. The paradox of ubiquitous infection yet rare disease, along with fragmented hypotheses (molecular mimicry, Pender, Aloisi, driver, and hit-and-run hypotheses), highlights the need for a unifying model. Here, we propose a hypothetical \"permissive-to-intrathecal activation model\" in which genetic susceptibility, age at primary infection, and environmental exposures collectively lead to immune control failure of EBV-infected B cells (impaired immune surveillance and self-tolerance), allowing them to reprogram, migrate to the CNS, and become the central pathological hub, where intrathecal B-cell activation drives T-cell-mediated injury. Within this model, existing hypotheses can be integrated as specific components of this cascade. Based on the model, we outline three therapeutic strategies (primary prevention, EBV-directed, and B-cell-directed). Beyond MS, its core concepts-permissive conditions, immune control failure, and intrathecal activation-might provide a conceptual framework for other EBV-associated CNS autoimmune diseases, including neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), despite limited epidemiological evidence. In this framework, disease-specific permissive conditions shape distinct patterns of immune control failure, which determines EBV's divergent roles, while intrathecal B-cell activation remains a shared process. This review may advance mechanistic understanding of EBV-driven CNS autoimmunity and provide a theoretical basis for precision intervention.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104237"},"PeriodicalIF":9.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The MDA5-RNA-autoantibody axis in anti-MDA5 dermatomyositis: Structural biology, pathogenic mechanisms, and mechanism-guided therapy. 抗mda5皮肌炎的mda5 - rna -自身抗体轴:结构生物学、致病机制和机制指导治疗
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-12 DOI: 10.1016/j.autrev.2026.104247
Kaiwen Wang, Jiangfeng Zhao, Li Guo, Zhiwei Chen, Yakai Fu, Wanlong Wu, Shuang Ye
{"title":"The MDA5-RNA-autoantibody axis in anti-MDA5 dermatomyositis: Structural biology, pathogenic mechanisms, and mechanism-guided therapy.","authors":"Kaiwen Wang, Jiangfeng Zhao, Li Guo, Zhiwei Chen, Yakai Fu, Wanlong Wu, Shuang Ye","doi":"10.1016/j.autrev.2026.104247","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104247","url":null,"abstract":"&lt;p&gt;&lt;p&gt;Anti-MDA5&lt;sup&gt;+&lt;/sup&gt; dermatomyositis is among the most severe subtypes of idiopathic inflammatory myopathy, characterized by a vasculopathic skin phenotype and a high risk of rapidly progressive interstitial lung disease (RP-ILD). Mortality is not a single fixed value: it varies with the presence of RP-ILD, age, oxygenation, pulmonary function, ferritin, inflammatory status, disease severity at enrolment, treatment, and the time point at which outcomes are assessed, and exceeds 50% at 6-months in patients who progress to respiratory failure. The autoantigen MDA5 is a cytosolic dsRNA sensor that assembles cooperatively into helical filaments on long duplexes and nucleates MAVS-driven type I interferon signaling. Anti-MDA5 antibody titer tracks disease activity and treatment response, the type I interferon signature is elevated in blood, skin and muscle, and IFIH1 gain-of-function mutations that stabilize MDA5 filaments on endogenous RNA cause interferonopathies that share a mechanistic node-impaired filament turnover-with this disease, although their clinical phenotypes differ substantially. This review synthesizes structural, genetic, immunological, and therapeutic evidence to reframe anti-MDA5&lt;sup&gt;+&lt;/sup&gt; DM as an acquired, autoantibody-amplified disorder of MDA5-RNA sensing. We propose a dual-axis hypothesis: an intracellular route, which is a structural prediction that has not been experimentally validated, in which antibody binding may modulate MDA5 filament dynamics; and an extracellular route, supported by peer-reviewed evidence that RNA-containing anti-MDA5 immune complexes induce IFN-α and, for its FcγRI-dependent uptake and multi-sensor amplification steps, by preliminary findings reported in a preprint, in which MDA5-RNA-antibody complexes are captured by Fcγ receptor-expressing cells. The framework is consistent with existing clinical and mechanistic data and identifies four candidate therapeutic nodes: antibody clearance, FcγR/TLR blockade, RLR modulation, and JAK-STAT inhibition. Among current therapies, JAK inhibition is supported by the strongest available comparative evidence, although that evidence is observational and of low certainty rather than randomized. The medium-term agenda requires structural validation of the intracellular axis, mapping of the self-dsRNA ligand pool, and randomized trials of antibody- and Fc-receptor-directed therapies. TAKE-HOME MESSAGES: Anti-MDA5&lt;sup&gt;+&lt;/sup&gt; dermatomyositis is associated with a high risk of rapidly progressive interstitial lung disease and substantial early mortality, particularly in patients with severe or progressive lung disease. We propose that a type I interferon amplification loop, sustained by MDA5-RNA-autoantibody immune complexes, is central to this process. On the basis of observational, non-randomized comparative evidence, we suggest that a JAK inhibitor be considered early as part of combination induction therapy in patients with active or progressive interstitial ","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"26 2","pages":"104247"},"PeriodicalIF":9.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Representation of women and sex-disaggregated outcomes of trials in ANCA-associated vasculitis. anca相关血管炎试验中女性的代表性和按性别分类的结果。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-12 DOI: 10.1016/j.autrev.2026.104243
Vanja Ivković, Annette Bruchfeld, Lauren Floyd, Jennifer S Lees, Karl Emil Nelveg-Kristensen, Sarah Soyeon Oh, Peong Gang Park, Jae Il Shin, Maria Weiner, Andreas Kronbichler, Kate I Stevens
{"title":"Representation of women and sex-disaggregated outcomes of trials in ANCA-associated vasculitis.","authors":"Vanja Ivković, Annette Bruchfeld, Lauren Floyd, Jennifer S Lees, Karl Emil Nelveg-Kristensen, Sarah Soyeon Oh, Peong Gang Park, Jae Il Shin, Maria Weiner, Andreas Kronbichler, Kate I Stevens","doi":"10.1016/j.autrev.2026.104243","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104243","url":null,"abstract":"<p><strong>Importance: </strong>Women are generally underrepresented in randomized controlled trials (RCTs). Data on the representation of women, and on potential differences in outcomes between women and men, are lacking for RCTs in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).</p><p><strong>Objective: </strong>We sought to evaluate representation of women and reporting of sex-disaggregated outcomes in RCTs of AAV.</p><p><strong>Data sources: </strong>A PubMed, Embase, and Cochrane CENTRAL search was carried out for RCTs on AAV published from the beginning of indexation to 1st May 2025.</p><p><strong>Study selection: </strong>We included trials enrolling patients with AAV. Studies which were not RCTs or did not explore AAV; were not main reports of RCTs; enrolled only a minority of patients with AAV; or in which only a part of the study was an RCT were excluded.</p><p><strong>Data extraction and synthesis: </strong>Two authors screened publications, one extracted the data, and another verified a random sample for accuracy. The review was registered prospectively in PROSPERO (CRD420251000135).</p><p><strong>Main outcomes and measures: </strong>Representation of women was expressed as a percentage of enrollment and as the participation-to-prevalence ratio (PPR), defined as the ratio between enrollment of women and prevalence of AAV in women, calculated using a random-effects meta-analysis.</p><p><strong>Results: </strong>Fifty-six RCTs were included, of which 54 (96%) trials enrolling 5284 patients provided data on sex. A total of 2418 (45.8%) patients were women (weighted PPR of 0.95; 0.90-1.00). Using time- and location-specific prevalence estimates (38 trials), the weighted PPR was 0.86 (0.74-0.99). Women were underrepresented (PPR < 0.8) in 13 (24%) and overrepresented (PPR ≥1.2) in seven (13%) RCTs. Women were more frequently recruited in RCTs based in Asia and Australia (56.9%) compared to European (41.9%) and global (two or more continents) RCTs (48.3%) (p < 0.001). Enrollment of women increased across five-year time periods (p for trend = 0.02) but was not associated with RCT size or quality. No trial compared baseline characteristics across sex. Only three studies (5%) reported sex-disaggregated outcomes, one of them in the main text. Including follow-up publications, sex-disaggregated outcomes were available for only 20 of 56 trials (36%).</p><p><strong>Conclusions and relevance: </strong>Overall, women are not underrepresented in RCTs performed in AAV, although representation varied considerably between trials. More importantly, trials almost never report sex-disaggregated outcomes and very rarely report whether differences may exist between women and men. To prevent disparity of care, these gaps need to be addressed, and reporting of sex-disaggregated outcomes should become a standard in RCTs.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104243"},"PeriodicalIF":9.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond association in PAD2 and PAD4 research in rheumatoid arthritis. 在类风湿关节炎的PAD2和PAD4研究中超越关联。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-12 DOI: 10.1016/j.autrev.2026.104252
Xia Qu, Cheng Luo, Xuanyan Liu, Chunlian Li, Bo Chen
{"title":"Beyond association in PAD2 and PAD4 research in rheumatoid arthritis.","authors":"Xia Qu, Cheng Luo, Xuanyan Liu, Chunlian Li, Bo Chen","doi":"10.1016/j.autrev.2026.104252","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104252","url":null,"abstract":"","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"25 12","pages":"104252"},"PeriodicalIF":9.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis. deucravacitinib与安慰剂治疗活动性银屑病关节炎的疗效和安全性:一项系统评价和荟萃分析。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-12 DOI: 10.1016/j.autrev.2026.104251
Syed Faqeer Hussain Bokhari, Ayesha Faheem, Sarah Ali, Maryum Choudhary, Samia Arif, Minahil Saif, Saira Shamim, Asma Iqbal, Muqaddas Arshad, F N U Sabeen, Aeyza Nasir, Amna Javed Ch, Jawad Hasan, Amatul Noor
{"title":"Efficacy and safety of deucravacitinib versus placebo in active psoriatic arthritis: a systematic review and meta-analysis.","authors":"Syed Faqeer Hussain Bokhari, Ayesha Faheem, Sarah Ali, Maryum Choudhary, Samia Arif, Minahil Saif, Saira Shamim, Asma Iqbal, Muqaddas Arshad, F N U Sabeen, Aeyza Nasir, Amna Javed Ch, Jawad Hasan, Amatul Noor","doi":"10.1016/j.autrev.2026.104251","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104251","url":null,"abstract":"<p><strong>Background: </strong>Deucravacitinib is a first-in-class selective TYK2 inhibitor approved for plaque psoriasis. No comprehensive systematic review and meta-analysis (SRMA) has evaluated its multidomain efficacy and safety in psoriatic arthritis (PsA).</p><p><strong>Methods: </strong>We conducted a PRISMA compliant SRMA comparing deucravacitinib 6 mg once daily versus placebo in adults with active PsA. Effect sizes were expressed as odds ratios (OR) or mean differences (MD) with 95% confidence intervals. Heterogeneity was assessed using the I<sup>2</sup> statistic and the certainty of evidence was graded using the GRADE framework.</p><p><strong>Results: </strong>Three RCTs (N = 1430) were included, all rated low risk of bias. Deucravacitinib significantly outperformed placebo across all ACR response thresholds (ACR20: OR 2.07 [1.68-2.56]; ACR50: OR 2.13 [1.63-2.79]; ACR70: OR 2.42 [1.61-3.63]). Significant benefits were observed across composite disease activity indices including DAS28-CRP remission (OR 2.14 [1.62-2.82]) and DAPSA remission (OR 3.50 [2.04-6.00]), as well as minimal disease activity. Dermatological outcomes showed large treatment effects though with substantial heterogeneity. Significant improvements were also demonstrated in physical function, dactylitis resolution, disease-specific quality of life, fatigue, pain interference, and all four WPAI domains. The safety profile was comparable to placebo, with no significant differences in total adverse events (OR 1.30 [0.79-2.16]), serious adverse events (OR 1.00 [0.45-2.20]), or gastrointestinal events (OR 0.73 [0.42-1.25]).</p><p><strong>Conclusions: </strong>Deucravacitinib 6 mg once daily demonstrates consistent, multidomain superiority over placebo in active PsA at 16 weeks without excess adverse event burden. Head-to-head trials and longer-term data are needed to define its position in the treatment algorithm.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"26 2","pages":"104251"},"PeriodicalIF":9.8,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149401512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic and environmental etiology of pediatric and adult-onset multiple sclerosis. 儿童和成人多发性硬化症的遗传和环境病因学。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-11 DOI: 10.1016/j.autrev.2026.104234
Ellie Kim, Lucinda P Lawson, Elizabeth Wilson, W Daniel Chapman, Aram Zabeti, Leah C Kottyan, Matthew T Weirauch
{"title":"Genetic and environmental etiology of pediatric and adult-onset multiple sclerosis.","authors":"Ellie Kim, Lucinda P Lawson, Elizabeth Wilson, W Daniel Chapman, Aram Zabeti, Leah C Kottyan, Matthew T Weirauch","doi":"10.1016/j.autrev.2026.104234","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104234","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with complex etiology shaped by both genetic susceptibility and environmental exposures. This review synthesizes classic and emerging literature to provide an integrated framework for understanding MS risk, with emphasis on gene-environment interactions and their contribution to disease. We compile a comprehensive linkage disequilibrium-expanded MS genetic risk variant set identified through genome-wide association studies, including annotation of risk alleles. We discuss insights obtained from functional genomics studies that illuminate genotype-dependent regulatory mechanisms. Environmentally, we assess evidence implicating infectious agents (most notably Epstein-Barr virus) as well as vitamin D insufficiency, obesity, smoking, heavy metal exposure, and the gut microbiome, highlighting epidemiologic associations and areas where mechanistic understanding remains limited. We highlight current knowledge on individuals with pediatric-onset MS (POMS), a population underrepresented in etiologic studies despite its distinct clinical and immunological features. We compare genetic burden, environmental exposures, and immunopathology between pediatric- and adult-onset MS, identifying shared determinants as well as age-specific risk modifiers. Finally, we propose important future directions, including improved ancestry and age-range representation, functional validation of risk loci, and the use of treatment-naïve, tissue-derived patient samples.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104234"},"PeriodicalIF":9.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treat-to-target strategies in juvenile systemic lupus erythematosus: A scoping review of current evidence and future directions. 青少年系统性红斑狼疮的治疗目标策略:当前证据和未来方向的范围审查。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-11 DOI: 10.1016/j.autrev.2026.104242
Valentina Natoli, Emily Jones, Michael W Beresford, Eve M D Smith
{"title":"Treat-to-target strategies in juvenile systemic lupus erythematosus: A scoping review of current evidence and future directions.","authors":"Valentina Natoli, Emily Jones, Michael W Beresford, Eve M D Smith","doi":"10.1016/j.autrev.2026.104242","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104242","url":null,"abstract":"<p><p>Treat-to-target (T2T) has emerged as a promising strategy to potentially improve long-term outcomes in systemic lupus erythematosus (SLE). While T2T principles are well established in adult-onset disease, their adaptation to juvenile-onset SLE (jSLE) is more recent, with evidence remaining largely observational. To synthesise and map the current evidence, a systematic search was conducted in PubMed, Scopus, Ovid and Web of Science using terms related to jSLE, T2T, remission and Lupus Low Disease Activity State (LLDAS). Peer-reviewed English-language studies including patients diagnosed before age 18 were eligible if they addressed target development or validation, implementation strategies, associations with outcomes, facilitators or barriers to target attainment, biomarkers or lupus nephritis in the context of T2T. Reviews, editorials, conference abstracts, non-English publications and non-paediatric T2T studies were excluded. Of 347 identified records, 24 met inclusion criteria. These included work on target development and validation, implementation approaches and evaluation of clinical impact. Across studies, 67-100% of patients reached LLDAS or childhood LLDAS, 11-61% achieved remission on-steroids, and 2-31% achieved remission off-steroids, depending on definitions. Target attainment was consistently associated with fewer flares and less damage. Factors such as absence of renal disease, early use of mycophenolate mofetil and biologics supported target achievement, while African/Caribbean ethnicity, renal involvement, high disease activity at onset, and the glucocorticoid dose negatively influenced the likelihood of reaching targets. Although evidence is growing, variability in target definitions and study design limits comparability. Paediatric-specific targets represent an important step forward, with priorities now including validation, biomarker integration and prospective evaluation in a clinical trial.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104242"},"PeriodicalIF":9.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulatory T cells in kidney diseases: context-dependent functions and therapeutic potential. 肾脏疾病中的调节性T细胞:环境依赖的功能和治疗潜力。
IF 9.8 1区 医学
Autoimmunity reviews Pub Date : 2026-11-11 DOI: 10.1016/j.autrev.2026.104241
Ling Liu, Ye Chen, Lingjuan Liu, Jingyuan Xie, Song Guo Zheng
{"title":"Regulatory T cells in kidney diseases: context-dependent functions and therapeutic potential.","authors":"Ling Liu, Ye Chen, Lingjuan Liu, Jingyuan Xie, Song Guo Zheng","doi":"10.1016/j.autrev.2026.104241","DOIUrl":"https://doi.org/10.1016/j.autrev.2026.104241","url":null,"abstract":"<p><p>Kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), IgA nephropathy (IgAN), lupus nephritis (LN), and kidney transplantation, share features of immune dysregulation, persistent inflammation, and progressive fibrosis. Regulatory T cells (Tregs) are central to immune tolerance in the kidney, yet their function is not uniform: it is shaped by developmental origin, disease etiology, disease stage and the metabolic and inflammatory tone of the renal microenvironment. Single-cell and spatially resolved profiling has revealed tissue-resident, activated, dysfunctional, and senescent Treg states in the injured kidney, and has begun to define the renal Treg niche. Building on this evidence, we propose an etiology- and stage-stratified framework in which Tregs protect against acute injury, promote repair, or, under specific conditions, contribute to fibrotic remodeling. This framework rationalizes therapeutic targeting: cytokine and small-molecule Treg expansion (notably low-dose IL-2), Treg-compatible optimization of conventional immunosuppression, adoptive polyclonal and antigen-specific CAR/TCR-Treg therapies, and metabolic or tissue-targeted engineering should be matched to disease etiology and stage. Integrating spatial multi-omics, lineage-stabilizing strategies, and standardized manufacturing and monitoring will be essential to translate Treg-based therapies into precision treatments for kidney diseases.</p>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":" ","pages":"104241"},"PeriodicalIF":9.8,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书